The significant weight loss seen in studies demonstrates the effectiveness of these pharmaceutical treatments
Regular monitoring of weight, blood sugar levels, and potential side effects is essential during semaglutide therapy
Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans
These are the main differences between the different types of GLP-1 agonists: Semaglutide (Ozempic, Wegovy) Strong anti-inflammatory potential Powerful metabolic benefits and weight loss Longer duration, but higher risk of GI and vestibular side effects Only works on immune cells receptors( not on adipose tissue directly) Tirzepatide (Mounjaro, Zepbound) Works on both GLP-1 and GIP receptors (targeting adipose tissue receptors) Strong anti-inflammatory and insulin-sensitivity effects Significant weight loss Higher likelihood of GI issues in some women Liraglutide (Saxenda) Daily injection Lowest weight loss and inflammation benefits Often gentler on the gut Poorer response for Lipedema in later stages The best choice often depends on: Your gut health Whether you struggle with dizziness or vestibular issues Your appetite levels Your sensitivity to medications Your nutrition status For Lipedema patients, Tirzepatide remains the best therapeutic choice to have a significant benefit on the adipose tissue
We understand that this change may be unexpected, but rest assured, there are alternative options available
